AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 131 min read$TAK

Shannon Elaine Mary sold $68K of TAK

Shannon Elaine Mary (Pres., Global Supply & Quality) sold 3,978 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 on 2026-08-10.

Original reporting
SEC EDGAR · Shannon Elaine Mary
Published Aug 13, 2026, 1:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TAK
Neutral
high confidence
Mentioned
$TAK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may note the insider sale, but the filing does not provide new fundamental information that should drive repricing.

03

What to watch

Insider sales often reflect diversification, taxes, or personal liquidity needs; without additional context, this is not strong evidence of deteriorating fundamentals.

Relevance 3/10Novelty 2/10Timing: Filed 2026-08-12 for a sale dated 2026-08-10.

Background

The article is a SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd.

Company-level read

Ticker impact

$TAKNeutralHigh confidence
Context

Takeda’s Form 4 shows insider Shannon Elaine Mary sold 3,978 shares at $17.10 on 2026-08-10, totaling about $68.0K.

Expected impact

Likely negligible near-term impact; any effect would be limited to short-lived sentiment rather than fundamentals.

Evidence & confidence

The filing discloses a modest transaction size ($68,023.80) and does not include new company guidance, operational updates, or regulatory/legal developments.

Market effects

Sector

No clear sector read-through from a small, routine insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Absence of a 10b5-1 plan could be interpreted by some traders as less “scheduled,” but the disclosed dollar value is still small.

Key entities

  • issuer
    Takeda Pharmaceutical Co Ltd

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Shannon Elaine Mary

    Pres., Global Supply & Quality, reported the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TAK insider trading history →

Related articles

OCT 26
$AZNMedAI 8/10

AstraZeneca: Stomach Cancer Drug With $3 to $5 Billion Sales Potential, and One Significant Wrinkle

AstraZeneca (AZN) reported that its drug sone-ve doubled median survival in stomach cancer patients who had already tried at least two treatments, with median survival rising from 5.0 to 10.0 months. The company expects peak annual sales of $3B to $5B. Takeda (TAK) also reported positive results for its rival drug, arcotatug tavatecan, meeting both primary endpoints.

finance.yahoo.com3 min
OCT 23
$TAKHighAI 9/10

Takeda reports positive phase 3 trial results for gastric cancer drug

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) reported positive Phase 3 trial results for arcotatug tavatecan in gastric cancer patients, meeting overall and progression-free survival endpoints. Median overall survival was 10.2 months vs. 6.9 months for other treatments. The drug showed a 37.4% objective response rate. Takeda plans regulatory filings in Japan and China. The drug is not yet approved by the FDA.

investing.com2 min
OCT 19
$TAKLowAI 8/10

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Takeda's VERDICT trial showed that treating ulcerative colitis patients with ENTYVIO to achieve disease clearance (vs. symptomatic remission) prolonged time to complications by 70%. The study met its primary endpoint, with Group 3 (disease clearance) showing longer time to complications (HR 0.33, P=0.0014). Over 50% of patients in Group 3 achieved their target by Week 16. The trial also identified molecular patterns associated with early disease clearance.

elliotlakestandard.ca2 min